“Right-to-try” laws claim to help terminally patients by allowing them access to experimental drugs before they are approved, when, in fact, their purpose is to undermine and weaken the FDA and such laws strip legal and regulatory protections from patients using such drugs. Now advocates are making a new push to pass right-to-try by embedding it in the very law that funds the FDA. They might succeed if they encounter no opposition from constituents.
Cassandra Callender made national news a couple of years ago when at age 17 she was diagnosed with Hodgkin’s lymphoma and refused chemotherapy. The court ordered that she undergo appropriate treatment, but unfortunately she relapsed and chose treatment at a quack clinic in Mexico. Continuing to progress, she finally chose real medicine to treat her cancer. Let’s hope that it’s not too late to save her.
Since being given a slap on the wrist by the Texas Medical Board for his many years of peddling his antineoplastons, a treatment that’s never been shown to have significant anticancer activity, Stanislaw Burzynski is back in action again, preying on desperate cancer patients like it’s 1999.
Just over two years ago, the Society for Integrative Medicine issued clinical guidelines for breast cancer care. Now it’s updated them. Unfortunately, mixing cow pie with apple pie for a little longer doesn’t make the cow pie any better than it was last time.
This week, the FDA sent warning letters to 14 companies making unsupported claims that their products can treat cancer. Given the new administration’s determination to deregulate almost everything, but especially the FDA, is this the last time in the foreseeable future that such a crackdown will occur?
